PHASE I STUDY OF PHOTODYNAMIC THERAPY FOR SURFACE MALIGNANCIES

光动力疗法涉及使用光激活化合物 定位在肿瘤中，然后激活 化合物通过光的细胞毒性作用用于治疗 癌 目前的方案使用静脉内给药 血卟啉衍生物的Photofrin II制剂。 目前唯一批准用于人类的光敏剂。 然后将光输送到受影响的区域。 使用耦合到光传感器的光纤将光导向肿瘤。 氩/泵浦染料激光器。 血卟啉衍生物选择性 与某些正常组织相比，它位于肿瘤中。 的 这一机制目前还不清楚，但已经 在动物和患者中均有记录。 选择性保留 与聚焦光递送组合， 所涉及的区域允许选择性地破坏肿瘤， 对未受累正常组织的影响极小。 血啉 衍生光动力疗法在临床上可用于 肿瘤累及的解剖部位数量。

Photodynamic therapy involves the use of a light activated compound which localizes in tumor, followed by the activation of this compound by light for cytotoxic effects for the treatment of cancer. The current protocol uses the intravenous administration of the Photofrin II preparation of the hematoporphyrin derivative. the only currently approved photosensitizer for use in humans. This is followed by the delivery of light to the affected area. Light is directed at the tumor using optical fibers coupled to a argon/pumped dye laser. Hematoporphyrin derivative selectively localizes in tumor compared to certain normal tissues. The mechanism of this is not well understood at this time, but has been documented in both animals &nd in patients. Selective retention of the photosensitizer in combination with focal light delivery to the involved area permits selective destruction of tumor with minimal effect on uninvolved normal tissue. Hematoporphyrin derivative photodynamic therapy may be clinically useful in a number of anatomic sites involved by tumor.